Envair Technology, a specialist manufacturer of clean air and containment solutions for the healthcare, biotechnology and pharmaceutical industries, has announced the appointment of Andrew Ellison as its new CEO.
Ellison has played a pivotal role in the business for the past four years as Chief Financial Officer (CFO), with sales growing fivefold as the business enters new markets, develops new products and consolidates bolt-on acquisitions. As CEO he will maximise the opportunity to bring the full suite of Envair Technology products to the fast-growing containment market.
The new CEO will also oversee the group's continued expansion overseas, as demand continues to increase for its containment solutions. International sales currently contribute up to 30% of total revenue, with particularly strong growth in the US and Western Europe. Group revenues will exceed £20m in 2022, with staff headcount increasing to 150.
Ellison joined ONFAB in 2017 and was instrumental in preparing the business for investment from Foresight, enabling it to acquire Envair and TCS. Prior to joining the company, he spent the previous 15 years within high-growth, private equity-backed organisations, leading exits, MBOs and M&A activity. He worked with global manufacturing organisations, including Airbus and Parker Hannifin and spent time in China while studying for his MBA at Manchester Business School.
Chris Wardle, Investment Director at Foresight, said: "As CEO, Andrew will be a unifying leader across Envair Technology. He has proven experience in managing fast-growth businesses and has demonstrated excellent leadership during periods of change. We look forward to seeing him lead the company through this exciting next phase of growth."
Andrew said: "I've witnessed Envair Technology's rapid development over the past few years and I'm delighted to be leading the next stage of that journey as CEO. It's an exciting time for us, with further international expansion planned, a growing team and the recent move to a new site in Lancashire."